ADPT:NSD-Adaptive Biotechnologies Corp (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.86

Change

-0.28 (-3.44)%

Market Cap

USD 1.18B

Volume

0.63M

Avg Analyst Target

USD 12.10 (+53.94%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ADPT Stock Forecast & Price:
Based on the Adaptive Biotechnologies Corp stock forecasts from 4 analysts, the average analyst target price for Adaptive Biotechnologies Corp is USD 12.10 over the next 12 months. Adaptive Biotechnologies Corp’s average analyst rating is Under-perform. Stock Target Advisor’s own stock analysis of Adaptive Biotechnologies Corp is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Adaptive Biotechnologies Corp’s stock price was USD 7.86. Adaptive Biotechnologies Corp’s stock price has changed by -3.79% over the past week, +3.29% over the past month and -70.51% over the last year.

About Adaptive Biotechnologies Corp (ADPT:NSD)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research que ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.03 (+0.33%)

USD80.34B 24.98 17.08
REGN Regeneron Pharmaceuticals Inc

-5.40 (-0.73%)

USD80.18B 15.51 11.82
MRNA Moderna Inc

-2.23 (-1.27%)

USD67.38B 6.33 4.43
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+2.12 (+1.31%)

USD37.58B 3.75 1.66
GMAB Genmab AS

-0.52 (-1.16%)

USD29.87B 37.36 3.53
ALNY Alnylam Pharmaceuticals Inc

-4.41 (-2.11%)

USD26.17B N/A -26.97
SGEN Seagen Inc

-3.85 (-3.18%)

USD22.92B 55.02 -38.67
ARGX argenx NV ADR

-1.28 (-0.34%)

USD21.49B N/A -20.63
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ADPT

Symbol Name Weight Mer Price(Change) Market Cap
PBI:CA Purpose Best Ideas 0.00 % 0.75 %

-0.28 (-1.02%)

USD0.03B
PBI-B:CA Purpose Fund Corp. - Purp.. 0.00 % 0.79 %

N/A

USD7.73M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -71.99% 30% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.99% 30% F 20% F
Trailing 12 Months  
Capital Gain -69.87% 40% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.87% 40% F 23% F
Trailing 5 Years  
Capital Gain 457.45% 94% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 457.45% 94% A 96% A
Average Annual (5 Year Horizon)  
Capital Gain 558.95% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 558.95% 98% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,019.77% 2% F 1% F
Risk Adjusted Return 54.81% 95% A 88% B+
Market Capitalization 1.18B 86% B 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.96 16% F 23% F
Price/Book Ratio 2.43 42% F 34% F
Price / Cash Flow Ratio -6.10 70% C- 66% D
EV/EBITDA -3.90 77% C+ 73% C
Management Effectiveness  
Return on Equity -38.89% 70% C- 34% F
Return on Invested Capital -31.02% 71% C- 31% F
Return on Assets -14.83% 82% B- 31% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.35 51% F 34% F
Short Percent 5.30% 37% F 29% F
Beta 1.05 54% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector